ATE176502T1 - Dns sequenzen, rekombinante dns-moleküle sowie verfahren zur herstellung des an der lymphocyten- funktion assoziierten antigens-3 - Google Patents

Dns sequenzen, rekombinante dns-moleküle sowie verfahren zur herstellung des an der lymphocyten- funktion assoziierten antigens-3

Info

Publication number
ATE176502T1
ATE176502T1 AT88905552T AT88905552T ATE176502T1 AT E176502 T1 ATE176502 T1 AT E176502T1 AT 88905552 T AT88905552 T AT 88905552T AT 88905552 T AT88905552 T AT 88905552T AT E176502 T1 ATE176502 T1 AT E176502T1
Authority
AT
Austria
Prior art keywords
antigen
producing
dna sequences
lymphocyte function
recombinant dna
Prior art date
Application number
AT88905552T
Other languages
English (en)
Inventor
Barbara P Wallner
Timothy A Springer
Catherine Hession
Richard Tizard
Robert Mattaliano
Michael L Dustin
Original Assignee
Biogen Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE176502(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc, Dana Farber Cancer Inst Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of ATE176502T1 publication Critical patent/ATE176502T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88905552T 1987-06-03 1988-06-03 Dns sequenzen, rekombinante dns-moleküle sowie verfahren zur herstellung des an der lymphocyten- funktion assoziierten antigens-3 ATE176502T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/057,615 US4956281A (en) 1987-06-03 1987-06-03 DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3

Publications (1)

Publication Number Publication Date
ATE176502T1 true ATE176502T1 (de) 1999-02-15

Family

ID=22011704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88905552T ATE176502T1 (de) 1987-06-03 1988-06-03 Dns sequenzen, rekombinante dns-moleküle sowie verfahren zur herstellung des an der lymphocyten- funktion assoziierten antigens-3

Country Status (11)

Country Link
US (1) US4956281A (de)
EP (1) EP0315683B1 (de)
JP (1) JP2659781B2 (de)
AT (1) ATE176502T1 (de)
AU (1) AU634464B2 (de)
CA (1) CA1340232C (de)
DE (1) DE3856301T2 (de)
HU (1) HU211627A9 (de)
MX (1) MX9202970A (de)
SG (1) SG49653A1 (de)
WO (1) WO1988009820A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US6461825B1 (en) * 1987-09-30 2002-10-08 Sanofi (Societe Anonyme) Immunometric assay kit and method applicable to whole cells
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5328988A (en) * 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5395929A (en) * 1987-12-15 1995-03-07 Dana Farber Cancer Institute Isolated nucleic acid encoding the alpha subunit of the human leukocyte adhesion receptor
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
EP0362531B1 (de) 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
JPH04506666A (ja) * 1990-01-24 1992-11-19 バイオジェン，インコーポレイテッド ワクチンアジュバントとしてのｌｆａ―３
DE4008354A1 (de) * 1990-03-15 1991-09-19 Basf Ag Neues protein, seine herstellung und verwendung
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5871733A (en) * 1990-07-20 1999-02-16 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
CA2049449C (en) * 1990-08-20 1999-08-10 Fumiya Obata Hla-dr antigen gene and its nucleotide sequence and its use
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
AU660312B2 (en) * 1991-06-06 1995-06-22 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha LFA-3-like protein, derivatives thereof, genes thereof and processes for preparing the same
ES2169783T3 (es) * 1991-10-07 2002-07-16 Biogen Inc Metodos para mejorar la tolerancia de aloinjertos o xenoinjertos por administracion de proteinas de fijacion lfa-3 o cd2.
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5856928A (en) * 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
US6465253B1 (en) * 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
EP0867449A4 (de) * 1995-04-19 2000-08-09 Kanegafuchi Chemical Ind Zellädhasionsprotein, dier enthaltende immunsuppressive mittel, sowie immunsuppressiva, die zellen enthalten, welche damit induziert wurden
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP4104704B2 (ja) * 1997-10-01 2008-06-18 シスメックス株式会社 自動分析装置用洗浄剤
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
WO2000012113A2 (en) * 1998-08-31 2000-03-09 Biogen, Inc. Method of modulating memory effector t-cells using a cd2-binding agent, and compositions
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US7851212B2 (en) * 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
US20040033605A1 (en) * 2000-09-20 2004-02-19 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US7858095B2 (en) * 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
PT1497438E (pt) * 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
CN1953766A (zh) * 2004-02-06 2007-04-25 安斯泰来美国有限公司 治疗皮肤病的方法
MXPA06012744A (es) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento.
WO2005115436A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
EP2224955A4 (de) 2007-11-27 2011-02-16 Univ British Columbia 14-3-3 antagonisten zur prävention und behandlung von arthritis
CA2754741C (en) * 2009-03-11 2019-02-12 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
JP6844939B2 (ja) 2011-10-21 2021-03-17 オ−グレックス ライフ サイエンシズ コーポレイション シトルリン化１４−３−３由来の抗原、及び関節リウマチの診断におけるそれの使用
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3377363D1 (en) * 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4728927A (en) * 1984-09-28 1988-03-01 Aman James A Apparatus and method for performing comparison of two signals

Also Published As

Publication number Publication date
WO1988009820A1 (en) 1988-12-15
EP0315683B1 (de) 1999-02-03
HK1009291A1 (en) 1999-05-28
DE3856301T2 (de) 1999-07-15
DE3856301D1 (de) 1999-03-18
HU211627A9 (en) 1995-12-28
AU634464B2 (en) 1993-02-25
EP0315683A4 (de) 1990-02-05
SG49653A1 (en) 1998-06-15
MX9202970A (es) 1992-07-01
JP2659781B2 (ja) 1997-09-30
CA1340232C (en) 1998-12-15
JPH02501113A (ja) 1990-04-19
US4956281A (en) 1990-09-11
AU1955288A (en) 1989-01-04
EP0315683A1 (de) 1989-05-17

Similar Documents

Publication Publication Date Title
ATE176502T1 (de) Dns sequenzen, rekombinante dns-moleküle sowie verfahren zur herstellung des an der lymphocyten- funktion assoziierten antigens-3
ATE396735T1 (de) Hybride immunglobuline zur verwendung in therapeutischen verfahren
NO970155L (no) Kunstig ekstracellulær biologisk matrise samt fremgangsmåte ved fremstilling derav
AU4644689A (en) Hybrid procoagulant proteins
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
DE3852011D1 (de) Verfahren zur Herstellung von Polybutenen mit verbesserter Reaktionsfähigkeit mittels Bortrifluorid-Katalysatoren.
ATE193724T1 (de) Cd2 bindender bereich für das lymphocyten- funktion assoziierte antigen-3
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
DE68928934D1 (de) Verfahren zur herstellung von menschlicher dnase
DE3667179D1 (de) Verfahren zur ausbeuteverbesserung von destillaten beim kracken mit wasserstoff liefernden verduennungsmitteln.
DE3783897D1 (de) Verfahren zur herstellung von matrizen fuer plattierungsverfahren.
DE3884356D1 (de) Verfahren zur Herstellung von Fremdprotein in Hefe, Rekombinant DNS, Transformant.
NO864759D0 (no) Eutaryotiske fusjonsproteiner, fremstilling og anvendelse derav samt middel til gjennomfoering av fremgangsmaaten.
DK216589D0 (da) Dna sekvenser, rekombinante dna molekyler samt fremgangsmaader til fresmtilling af oploeselige t4-proteiner
DE69334211D1 (de) Multidrug resistenz gen
HU892558D0 (en) Process and preparation for the induction of a joint
ATE306549T1 (de) C-c ckr-1, ein c-c chemokin rezeptor
EP0091527A3 (de) DNS Sequenzen, rekombinante DNS Moleküle und Verfahren zur Herstellung von menschlichem Serum Albumin ähnlichen Polypeptiden
FI863626A7 (fi) DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
DE3864512D1 (de) Verfahren zur herstellung von kandis mit gepressten gaszellen.
DK260987D0 (da) Fremgangsmaade til fremstilling af et humant protein samt dna-sekvens til anvendelse ved udoevelse af fremgangsmaaden
BR9712793A (pt) Fatores homólogos (fhfs) ao fator do desenvolvimento de fibroblasto e métodos de uso
DE3679890D1 (de) Verfahren zur herstellung von mittels nitriddispersionen verstaerkten legierungen.
DE3678296D1 (de) Oberflaechenbehandlungszusammensetzung fuer glasfasern, verfahren zur beschichtung von glasfasern mit dieser zusammensetzung und verfahren zur herstellung von mit glasfasern verstaerkten polyepoxid-gegenstaenden.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee